| SANOFI |
SANOFI |
92%
|
Under the Sanofi Agreement, we granted to Sanofi a worldwide exclusive license to develop, manufacture and commercialize certain lead compounds generated during the collaboration |
| GENZYME-CORPORATION |
GENZYME-CORPORATION |
90%
|
On July 7, 2020, we entered into a collaboration agreement, or the Original Sanofi Agreement, with Genzyme Corporation, a subsidiary of Sanofi, to co-develop drug candidates directed to two biologica… |
| CCCC |
C4 Therapeutics, Inc. |
72%
|
Reciprocal relationship from CCCC graph: Reciprocal relationship from KYMR graph: current or future product candidates over current treatment options or alternative treatments, including future alter… |
| CCCC |
C4 Therapeutics, Inc. |
72%
|
current or future product candidates over current treatment options or alternative treatments, including future alternative treatments; • the willingness of the target patient population to try new t… |
| GILD |
Gilead Sciences, Inc. |
72%
|
Reciprocal relationship from GILD graph: Reciprocal relationship from KYMR graph: nties associated with product development, we are unable to predict the timing or amount of increased expenses or whe… |
| GILD |
Gilead Sciences, Inc. |
72%
|
nties associated with product development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able … |
| GLUE |
Monte Rosa Therapeutics, Inc. |
72%
|
Reciprocal relationship from GLUE graph: current or future product candidates over current treatment options or alternative treatments, including future alternative treatments; • the willingness of t… |
| JNJ |
Johnson & Johnson |
72%
|
current or future product candidates over current treatment options or alternative treatments, including future alternative treatments; • the willingness of the target patient population to try new t… |
| JNJ |
Johnson & Johnson |
72%
|
Reciprocal relationship from JNJ graph: Reciprocal relationship from KYMR graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from KYMR graph: Reciprocal relationship from JNJ grap… |
| NRIX |
Nurix Therapeutics, Inc. |
72%
|
Reciprocal relationship from NRIX graph: Reciprocal relationship from KYMR graph: current or future product candidates over current treatment options or alternative treatments, including future alter… |
| NRIX |
Nurix Therapeutics, Inc. |
72%
|
current or future product candidates over current treatment options or alternative treatments, including future alternative treatments; • the willingness of the target patient population to try new t… |
| NVSEF |
Novartis AG |
72%
|
ons by the U.S. Congress, the U.S. courts, the USPTO and the relevant law-making bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would we… |
| NVSEF |
Novartis AG |
72%
|
Reciprocal relationship from NVSEF graph: Reciprocal relationship from KYMR graph: ons by the U.S. Congress, the U.S. courts, the USPTO and the relevant law-making bodies in other countries, the laws… |
| SNYNF |
Sanofi |
72%
|
Reciprocal relationship from SNYNF graph: Reciprocal relationship from KYMR graph: ch on the targets, and Vertex was responsible for development, manufacturing, and commercialization of the product c… |
| SNYNF |
Sanofi |
72%
|
ch on the targets, and Vertex was responsible for development, manufacturing, and commercialization of the product candidates after it exercises its option to license. The initial research term of th… |
| VRTX |
Vertex Pharmaceuticals Incorporated |
72%
|
Reciprocal relationship from VRTX graph: Reciprocal relationship from KYMR graph: Reciprocal relationship from VRTX graph: Reciprocal relationship from KYMR graph: Reciprocal relationship from VRTX g… |
| VRTX |
Vertex Pharmaceuticals Incorporated |
72%
|
ess overall. Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to … |
| ARVINAS-INC-C4-THERAPEUTICS-INC-NURIX-THERAPEUTI |
ARVINAS-INC-C4-THERAPEUTICS-INC-NURIX-THERAPEUTI |
62%
|
current or future product candidates over current treatment options or alternative treatments, including future alternative treatments; • the willingness of the target patient population to try new t… |
| FOGHORN-THERAPEUTICS-INC |
FOGHORN-THERAPEUTICS-INC |
62%
|
current or future product candidates over current treatment options or alternative treatments, including future alternative treatments; • the willingness of the target patient population to try new t… |
| USA-LLC |
USA-LLC |
62%
|
ies, we had the ability to offer and sell up to an aggregate amount of $300.0 million of our common stock from time to time in “at-the-market” offerings, subject to the limitations thereof. From Octo… |
